Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Jan 10

PMID 30622535

Citations 66

Authors

Franziska Eckert

Karin Schilbach

Lukas Klumpp

Lilia Bardoscia

Efe Cumhur Sezgin

Matthias Schwab

Daniel Zips

Stephan M Huber

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy has been established as standard of care in different tumor entities. After the first reports on synergistic effects with radiotherapy and the induction of abscopal effects-tumor shrinkage outside the irradiated volume attributed to immunological effects of radiotherapy-several treatment combinations have been evaluated. Different immunotherapy strategies (e.g., immune checkpoint inhibition, vaccination, cytokine based therapies) have been combined with local tumor irradiation in preclinical models. Clinical trials are ongoing in different cancer entities with a broad range of immunotherapeutics and radiation schedules. SDF-1 (CXCL12)/CXCR4 signaling has been described to play a major role in tumor biology, especially in hypoxia adaptation, metastasis and migration. Local tumor irradiation is a known inducer of SDF-1 expression and release. CXCR4 also plays a major role in immunological processes. CXCR4 antagonists have been approved for the use of hematopoietic stem cell mobilization from the bone marrow. In addition, several groups reported an influence of the SDF-1/CXCR4 axis on intratumoral immune cell subsets and anti-tumor immune response. The aim of this review is to merge the knowledge on the role of SDF-1/CXCR4 in tumor biology, radiotherapy and immunotherapy of cancer and in combinatorial approaches.

Citing Articles

Nanoradiosensitizers in glioblastoma treatment: recent advances and future perspectives.

Liu M, Li T, Zhao M, Qian C, Wang R, Liu L Nanomedicine (Lond). 2024; 19(26):2229-2249.

PMID: 39311492 PMC: 11487349. DOI: 10.1080/17435889.2024.2395238.

Radiosynthesis and preclinical evaluation of a Ga-labeled tetrahydroisoquinoline-based ligand for PET imaging of C-X-C chemokine receptor type 4 in an animal model of glioblastoma.

Suwattananuruk P, Yaset S, Chotipanich C, Moldes-Anaya A, Sundset R, Berzaghi R EJNMMI Radiopharm Chem. 2024; 9(1):61.

PMID: 39162901 PMC: 11335985. DOI: 10.1186/s41181-024-00290-y.

Targeting cytokine and chemokine signaling pathways for cancer therapy.

Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K Signal Transduct Target Ther. 2024; 9(1):176.

PMID: 39034318 PMC: 11275440. DOI: 10.1038/s41392-024-01868-3.

Targeting CXCR4/CXCL12 axis via [Lu]Lu-DOTAGA.(SA.FAPi) with CXCR4 antagonist in triple-negative breast cancer.

Bao G, Wang Z, Liu L, Zhang B, Song S, Wang D Eur J Nucl Med Mol Imaging. 2024; 51(9):2744-2757.

PMID: 38587644 PMC: 11224082. DOI: 10.1007/s00259-024-06704-y.

Advancing cancer theranostics through biomimetics: A comprehensive review.

Anitha K, Chenchula S, Surendran V, Shvetank B, Ravula P, Milan R Heliyon. 2024; 10(6):e27692.

PMID: 38496894 PMC: 10944277. DOI: 10.1016/j.heliyon.2024.e27692.

References

Gu Q, He Y, Ji J, Yao Y, Shen W, Luo J . Hypoxia-inducible factor 1α (HIF-1α) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1α/CXCR4 pathway in non-small cell lung carcinoma cells. Oncotarget. 2015; 6(13):10893-907. PMC: 4484427. DOI: 10.18632/oncotarget.3535. View

Yang J, Kumar A, Vilgelm A, Chen S, Ayers G, Novitskiy S . Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res. 2018; 6(10):1186-1198. PMC: 6170679. DOI: 10.1158/2326-6066.CIR-18-0045. View

de Oliveira K, Guembarovski R, Guembarovski A, do Amaral Herrera A, Jorge Sobrinho W, Ariza C . CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer. Clin Exp Med. 2012; 13(3):211-9. DOI: 10.1007/s10238-012-0194-5. View

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

Teng M, Swann J, Von Scheidt B, Sharkey J, Zerafa N, McLaughlin N . Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res. 2010; 70(7):2665-74. DOI: 10.1158/0008-5472.CAN-09-1574. View

Kashyap M, Kumar D, Jones H, Amaya-Chanaga C, Choi M, Melo-Cardenas J . Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2015; 7(3):2809-22. PMC: 4823073. DOI: 10.18632/oncotarget.6465. View

Trautmann F, Cojoc M, Kurth I, Melin N, Bouchez L, Dubrovska A . CXCR4 as biomarker for radioresistant cancer stem cells. Int J Radiat Biol. 2014; 90(8):687-99. DOI: 10.3109/09553002.2014.906766. View

Abraham M, Pereg Y, Bulvik B, Klein S, Mishalian I, Wald H . Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34 Cells in Healthy Volunteers. Clin Cancer Res. 2017; 23(22):6790-6801. DOI: 10.1158/1078-0432.CCR-16-2919. View

Tabatabai G, Frank B, Mohle R, Weller M, Wick W . Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain. 2006; 129(Pt 9):2426-35. DOI: 10.1093/brain/awl173. View

10.

Nie Y, Han Y, Zou Y . CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med. 2008; 205(4):777-83. PMC: 2292218. DOI: 10.1084/jem.20072513. View

11.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

12.

Duda D, Kozin S, Kirkpatrick N, Xu L, Fukumura D, Jain R . CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. Clin Cancer Res. 2011; 17(8):2074-80. PMC: 3079023. DOI: 10.1158/1078-0432.CCR-10-2636. View

13.

Bilgin Y, de Greef G . Plerixafor for stem cell mobilization: the current status. Curr Opin Hematol. 2015; 23(1):67-71. DOI: 10.1097/MOH.0000000000000200. View

14.

Olson B, Jankowska-Gan E, Becker J, Vignali D, Burlingham W, McNeel D . Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol. 2012; 189(12):5590-601. PMC: 3735346. DOI: 10.4049/jimmunol.1201744. View

15.

Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R . Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 110(4):1225-32. DOI: 10.1182/blood-2006-12-064527. View

16.

Deaglio S, Dwyer K, Gao W, Friedman D, Usheva A, Erat A . Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204(6):1257-65. PMC: 2118603. DOI: 10.1084/jem.20062512. View

17.

Liu S, Alomran R, Chernikova S, Lartey F, Stafford J, Jang T . Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro Oncol. 2013; 16(1):21-8. PMC: 3870826. DOI: 10.1093/neuonc/not149. View

18.

Beider K, Begin M, Abraham M, Wald H, Weiss I, Wald O . CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2010; 39(3):282-92. DOI: 10.1016/j.exphem.2010.11.010. View

19.

Benedicto A, Romayor I, Arteta B . CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver. Oncol Rep. 2018; 39(4):2022-2030. DOI: 10.3892/or.2018.6254. View

20.

Lee C, Das B, Lin T, Grimes C, Zhang X, Lavezzi T . A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential. Br J Haematol. 2012; 158(1):79-90. PMC: 3374069. DOI: 10.1111/j.1365-2141.2012.09123.x. View